2019 Medicinal Chemistry Reviews

Volume 54, Chapter 20
Case History: Talzenna® (Talazoparib)—A Highly Potent, Orally Efficacious PARP Inhibitor for the Treatment of BRCA-Mutated, HER2-Negative Breast Cancer Patients
Bing Wang, Yuqiao Shen, Leonard E. Post

1. Introduction
2. Medicinal Chemistry Efforts Leading to the Discovery of Talazoparib
3. Scale-up Process Development for Talazoparib
4. Preclinical Characterization of Talazoparib
5. Clinical Results and FDA Approval
6. Conclusion

To purchase a copy of this chapter, go to our secure e-commerce site.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org